普洛药业(000739) - 2020 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2020 was ¥1,700,874,078.71, representing a 1.53% increase compared to ¥1,675,316,248.13 in the same period last year[2]. - Net profit attributable to shareholders was ¥154,733,354.57, a significant increase of 39.95% from ¥110,560,349.54 year-on-year[2]. - The net profit after deducting non-recurring gains and losses was ¥143,523,814.30, up 32.53% from ¥108,298,282.32 in the previous year[2]. - Basic and diluted earnings per share increased by 39.98% to ¥0.1313 from ¥0.0938 year-on-year[2]. - The total profit for the current period is 182,879,400.73, up from 135,759,796.21, reflecting a growth of approximately 34.7%[34]. - The operating profit for the current period is 183,685,799.79, compared to 137,594,789.08 in the previous period, indicating an increase of about 33.5%[34]. - The total comprehensive income attributable to the parent company is 154,671,543.46, compared to 111,468,880.72 from the previous period, showing an increase of around 38.7%[35]. Cash Flow - The net cash flow from operating activities decreased by 11.33% to ¥159,918,457.04 from ¥180,356,281.54 in the same period last year[2]. - The cash flow from operating activities for the current period is 1,221,756,838.97, slightly up from 1,220,695,166.06 in the previous period[40]. - The net cash inflow from operating activities was CNY 159,918,457.04, a decrease of 11.5% compared to CNY 180,356,281.54 in the previous year[41]. - Cash inflow from financing activities amounted to CNY 230,100,000.00, down 30.3% from CNY 330,000,000.00 in the previous year[43]. - The net cash flow from financing activities was CNY 174,996,223.92, compared to a net outflow of CNY 177,193,682.96 in the previous year[43]. Assets and Liabilities - Total assets at the end of the reporting period were ¥7,070,877,319.40, an increase of 8.41% from ¥6,522,585,923.42 at the end of the previous year[2]. - The total liabilities of the company reached CNY 3,148,218,988.66, up from CNY 2,754,599,136.14, which is an increase of about 14.3%[26]. - Total current liabilities increased to CNY 2,958,446,968.46 from CNY 2,561,555,217.89, reflecting an increase of approximately 15.5%[26]. - The company's total liabilities and equity amounted to CNY 7,070,877,319.40, an increase from CNY 6,522,585,923.42 at the end of 2019[29]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,597[7]. - The largest shareholder, Hongdian Group Holdings Co., Ltd., held 28.08% of the shares, totaling 330,941,729 shares[7]. - Net assets attributable to shareholders rose by 4.10% to ¥3,922,658,330.74 from ¥3,767,986,787.28 at the end of the previous year[2]. Operational Metrics - Research and development expenses for the quarter were CNY 85,657,799.67, up from CNY 72,318,564.80 in the previous year[32]. - The company reported a net investment loss of CNY -949,416.52, compared to a gain of CNY 6,263,366.84 in the same period last year[32]. - The company reported non-operating income of ¥11,209,540.27 during the reporting period[3]. Inventory and Receivables - Accounts receivable financing increased by 36.82% to CNY 306.90 million due to an increase in received notes[11]. - Prepayments rose by 59.89% to CNY 193.16 million primarily due to increased material payments[11]. - Inventory levels increased to CNY 1,040,712,223.62 from CNY 993,043,012.37, marking a growth of around 4.8%[23]. Compliance and Governance - The company has no overdue commitments from controlling shareholders or related parties during the reporting period[13]. - ProLogis Pharmaceuticals has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[22]. - The company has not reported any violations regarding external guarantees during the reporting period[21]. Other Financial Metrics - The company reported a decrease in cash received from borrowings by 30.27% to CNY 230.10 million[11]. - The company received tax refunds amounting to CNY 57,456,032.47, compared to CNY 52,604,111.62 in the previous year[41]. - The cash paid to employees increased to CNY 208,708,719.02, up 42.5% from CNY 146,473,949.58 in the previous year[41].